**AMGEN INC** Form 4 September 12, 2012

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB Number:

**OMB APPROVAL** 

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person \* SHARER KEVIN W

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Middle)

AMGEN INC [AMGN]

(Check all applicable)

(First) ONE AMGEN CENTER DRIVE

(Street)

3. Date of Earliest Transaction (Month/Day/Year)

\_X\_\_ Director 10% Owner Officer (give title Other (specify below)

09/11/2012

6. Individual or Joint/Group Filing(Check

Applicable Line)

4. If Amendment, Date Original Filed(Month/Day/Year)

> \_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

**THOUSAND** OAKS, CA 91320-1799

(City)	(State)	(Zip) Tal	ble I - Non-	Derivative S	Securi	ties Acquire	ed, Disposed of, o	or Beneficially	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	4. Securities Acquired (A) or nDisposed of (D) (Instr. 3, 4 and 5)  (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	09/11/2012		Code V M	Amount 1,598	(D)	Price \$ 62.55	102,616	D	
Common Stock	09/11/2012		M	193,402	A	\$ 62.55	296,018	D	
Common Stock	09/11/2012		M	79,625	A	\$ 58.43	375,643	D	
Common Stock	09/11/2012		G(1) V	274,625	A	\$ 0	423,119	I	Living Trust
Common Stock	09/11/2012		G(1) V	274,625	D	\$ 0	101,018 <u>(2)</u> <u>(3)</u>	D	

#### Edgar Filing: AMGEN INC - Form 4

Common Stock	09/11/2012	S	274,625	D	\$ 83.9618 <u>(4)</u>	148,494	I	Living Trust
Common Stock	09/11/2012	S	50,585	D	\$ 83.9639 (5)	97,909	I	Living Trust
Common Stock	09/11/2012	S	24,415	D	\$ 83.9665 (5)	73,494	I	Living Trust
Common Stock						4,433.6295 (6)	I	By 401(k) Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount of Number of Shares
Iso (Right to Buy)	\$ 62.55	09/11/2012		M		1,598	04/26/2011	04/26/2014	Common Stock	1,598
Nqso (Right to Buy)	\$ 62.55	09/11/2012		M		193,402	04/26/2008	04/26/2014	Common Stock	193,402
Nqso (Right to	\$ 58.43	09/11/2012		M		79,625	04/26/2011	04/26/2020	Common Stock	79,625

# **Reporting Owners**

Buy)

Reporting Owner Name / Address

Director 10% Owner Officer Other

X

Reporting Owners 2

Edgar Filing: AMGEN INC - Form 4

SHARER KEVIN W ONE AMGEN CENTER DRIVE THOUSAND OAKS, CA 91320-1799

## **Signatures**

/s/ Andrea Robinson, Attorney-in-Fact for Mr. Sharer

09/12/2012

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares are being transferred to the reporting person's Living Trust.
  - These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 9,250 RSUs which fully vest on 4/28/2013; 22,750 RSUs which vest in two equal annual installments of 11,375 each commencing 4/26/2013; 60,000 RSUs which
- (2) vest in two equal installments of 19,800 each on 4/25/2013 and 4/25/2014 and one installment of 20,400 on 4/25/2015; and 8,933 RSUs which vest in three installments of 2,947, 2,948 and 3,038 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 85 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- The price reported is an average price. The prices ranged from \$83.79 to \$84.12 per share. Full information regarding the number of (4) shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- The price reported is an average price. The prices ranged from \$83.795 to \$84.16 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- (6) These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

  Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

  Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3